Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases
2008 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases
Mössner, R. ; Thaci, D.; Mohr, J.; Pätzold, S.; Bertsch, H. P. ; Krüger, U. & Reich, K. (2008)
Archives of Dermatological Research, 300(3) pp. 101-105. DOI: https://doi.org/10.1007/s00403-008-0831-8
Documents & Media
Details
- Authors
- Mössner, Rotraut ; Thaci, Diamant; Mohr, Johannes; Pätzold, Sylvie; Bertsch, Hans Peter ; Krüger, Ullrich ; Reich, Kristian
- Abstract
- Infliximab is a monoclonal antibody directed against TNF-alpha. It has been approved for use in rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis and plaque-type psoriasis. In case reports, positive effects on pustular variants of psoriasis have also been reported. However, paradoxically, manifestation of pustular psoriasis and plaque-type psoriasis has been reported in patients treated with TNF antagonists including infliximab for other indications. Here, we report on 5 patients with chronic plaque-type psoriasis who developed palmoplantar pustulosis during or after discontinuation of infliximab therapy. In two of the five cases, manifestation of palmoplantar pustulosis was not accompanied by worsening of plaque-type psoriasis. Possibly, site-specific factors or a differential contribution of immunological processes modulated by TNF inhibitors to palmoplantar pustulosis and plaque-type psoriasis may have played a role.
- Issue Date
- 2008
- Journal
- Archives of Dermatological Research
- ISSN
- 0340-3696
- Language
- English